PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New drug cuts risk of deadly transplant side effect in half

First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant

New drug cuts risk of deadly transplant side effect in half
2012-12-09
(Press-News.org) ANN ARBOR, Mich. — A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.

Results of the study will be presented Dec. 9 at the 54th Annual Meeting of the American Society of Hematology.

"Graft-vs.-host disease is the most serious complication from transplant that limits our ability to offer it more broadly. Current prevention strategies have remained mostly unchanged over the past 20 years. This study has us cautiously excited that there may be a potential new way to prevent this condition," says lead study author Sung Choi, M.D., assistant professor of pediatrics at the U-M Medical School.

Vorinostat is currently approved by the U.S. Food and Drug Administration to treat certain types of cancer. But U-M researchers, led by senior study author Pavan Reddy, M.D., found in laboratory studies that the drug had anti-inflammatory effects as well – which they hypothesized could be useful in preventing graft-vs.-host disease, a condition in which the new donor cells begin attacking other cells in the patient's body.

Choi will present data on the first 47 patients enrolled on the study at the University of Michigan Comprehensive Cancer Center and Washington University. Participants were older adults who were undergoing a reduced-intensity bone marrow transplant with cells donated from a relative. Patients received standard medication used after a transplant to prevent graft-vs.-host disease. They also received vorinostat, which is given as a pill taken orally.

The researchers found vorinostat was safe and tolerable to give to this vulnerable population, with manageable side effects. In addition, rates of patient death and cancer relapse among the study participants were similar to historical averages.

The results mirror those found in the laboratory using mice. Reddy, an associate professor of internal medicine at the U-M Medical School, has been studying this approach in the lab for eight years.

"This is an entirely new approach to preventing graft-vs.-host disease," Choi says. Specifically, vorinostat targets histone deacetylases, which are different from the usual molecules targeted by traditional treatments.

"Vorinostat has a dual effect as an anti-cancer and an anti-inflammatory agent. That's what's potentially great about using it to prevent graft-vs.-host, because it may also help prevent the leukemia from returning," Choi says.

The study is continuing to enroll participants. The researchers hope next to test vorinostat in patients receiving a transplant from an unrelated donor, which carries an even greater risk of graft-vs.-host disease. This approach is not currently available outside of this clinical trial.



INFORMATION:



Note for patients: If you would like more information about the current clinical trial or about other treatment options at the University of Michigan Comprehensive Cancer Center, call the Cancer AnswerLine at 800-865-1125.

Additional authors:

From U-M: Thomas M. Braun, Ph.D.; Guoqing Hou, Ph.D.; John E. Levine, M.D., M.S.; Yaping Sun, M.D., Ph.D.; Daniel R. Couriel, M.D.; Lawrence Chang, M.D., M.P.H.; John M. Magenau, M.D.; Attaphol Pawarode; Carrie Kitko, M.D.; Sophie Paczesny, M.D., Ph.D.; Edward M. Peres, M.D.; Gregory A. Yanik, M.D.; Michael Lehmann, M.D.; and James L.M. Ferrara, M.D., D.Sc. From Washington University, St. Louis: John F. DiPersio, M.D., Ph.D., and Keith Stockerl-Goldstein, M.D. From Mie University Hospital, Japan: Isao Tawara, M.D., Ph.D. From Sutter East Bay Medical Foundation, Berkeley, Calif.: Oleg I. Krijanovski, Ph.D., M.D. From University of Alabama, Birmingham: Shin Mineishi, M.D. From University of Colorado Health Science Center: Charles A. Dinarello, M.D.

Funding: National Institutes of Allergy and Infectious Diseases grant A1091623-01, National Cancer Institute grant CA143379, Leukemia and Lymphoma Society, St. Baldrick's Foundation.

Disclosure: None

Reference: 54th Annual Meeting of the American Society of Hematology, Atlanta, Dec. 8-11, 2012. Abstract No. 740, Targeting Histone Deacetylases as a New Strategy for Graft Versus Host Disease Prevention.

Resources:

U-M Cancer AnswerLine, 800-865-1125
U-M Comprehensive Cancer Center, www.mcancer.org
Clinical trials at U-M, www.UMClinicalStudies.org/cancer


[Attachments] See images for this press release:
New drug cuts risk of deadly transplant side effect in half

ELSE PRESS RELEASES FROM THIS DATE:

New stem cell research, transplant strategies show promise to improve outcomes, reduce complications

2012-12-09
(ATLANTA, December 9, 2012) – Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell transplantation is effectively used today as a form of "replacement" therapy for patients with hard-to-treat ...

More than a third of high-risk leukemia patients respond to an experimental new drug

2012-12-09
A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial. In more than a third of participants, the leukemia was completely cleared from the bone marrow, and as a result, many of these patients were able to undergo potentially curative bone marrow transplants, according to investigators at the Johns Hopkins Kimmel Cancer Center and nine other academic medical centers around the world. Many of the participants who did well with the new drug, quizartinib or AC220, had ...

Studies challenge standards to improve treatment outcomes for patients with clotting disorders

2012-12-09
(ATLANTA, December 8, 2012) – Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. The studies evaluate long-held treatment standards and whether modifications in intensity and duration of therapy may offer equally effective outcomes while reducing toxicities and relapse rates. Although significant advances have been made in delivering new and improved therapies for clotting disorders, treatment still presents challenges; ...

Pre-clinical data shows Angiocidin effective against leukemia

2012-12-09
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments. George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9. AML causes certain white blood cells to stop maturing, resulting in their uncontrolled proliferation, which can lead to suppression of the immune system and often fatal secondary problems ...

Grizzly Beatz Provides High Quality Rap Instrumentals Across a Range of Genres

2012-12-09
Grizzly Beatz is an up-and-coming hip-hop producer that is been able to produce high-quality instrumentals for a range of different artists. Recently, Grizzly Beatz launch their own website and blog, allowing individuals to logon, listen to the beats that are available on the website, and then make a purchase for as little as $12. Their goal to provide high-quality beats, at a reasonable price for up-and-coming artists, has made them one of the premier online rep production services. With hundreds of different beats available, both on their website for purchase, as well ...

JBatch It v6 Redesigned to Support both 32 Bit and 64 Bit Windows 8

2012-12-09
iRedSoft Technology Inc announce the immediate release of JBatch It v6. JBatch It is a Batch Image Processor which takes away the mundane task of resizing, adding text caption, applying effects, fixing photo orientation and renaming image filenames. This would help increase productivity and minimizing mistakes made when handling large volume of digital photos. It supports JPEG, Single Page TIFF, PNG, BMP and GIF format. JBatch It v6 is a totally redesigned version of the application so as to support natively both the 32 Bit and 64 Bit Windows including the new Windows ...

Santa Brings Christmas Trees & Catnip to Sunrise Village This Holiday Season

2012-12-09
This year Santa is bringing Christmas trees and catnip to Sunrise Village, just a few of the many holiday happenings at the Puyallup shopping center. In addition to holiday sales and individual merchant events, Sunrise Village's holiday activities include: Nov. 23 til gone (9 am - 9 pm): Puyallup South Hill Lions Club Christmas Tree Sales Now through Dec. 16: Secret Santa Toy Drive at Sleep Country USA Dec. 8-9 (10 am - 4 pm): Santa Claws Pet Photos & Pet Adoptions at PetSmart Dec. 9 (9 am to Noon): Breakfast with Santa at The RAM Dec. 10 (6 - 9 pm): ...

Livewire Concepts, Inc. Raises Money For Kids!

2012-12-09
Livewire Concepts, Inc recently raised over $600 for Operation Smile, a nonprofit organization that performs surgeries for children born in third world countries with cleft palettes and other facial deformities. The cost of each surgery is $240, which is often too much for struggling families in impoverished nations The event was held at McFaddens in the Power and Light District. A raffle was held with giveaways from several local shops and restaurants as well as drink and food specials for all attending guests. The president of Livewire Concepts, C.J. Suggs said, "It's ...

Toddy Gear Celebrates the Holidays with Six New Seasonal Designs

2012-12-09
Toddy Gear is now selling its popular Toddy Smart Cloth and Wedge for a limited time featuring whimsical designs from the new "Season's Cleanings" collection. Peppo, Midnight Moose, and Winter Wonderland Smart Cloths bring the festive side to cleaning electronics screens, while Santa, Elf, and Rudolph Wedges will cradle your hand-held devices with style. These functional and fashionable microfiber cleaning products make wonderful stocking stuffers for family, friends, and coworkers. The Wedge is an innovative and practical accessory for a number of electronic ...

"It's Your Turn to Answer the Call" VoiceNation's Job Fair at Goodwill a Huge Success

2012-12-09
of over 120 job seekers at their recent job fair held at Goodwill of North Georgia's Oakwood Career Center. The job fair was part of VoiceNation's recruitment campaign entitled "It's Your Turn to Answer the Call". The company is looking to fulfill Customer Service Representative positions for full and part-time shifts at their expanding call center in Buford. VoiceNation is one of the fastest growing answering services in the industry. Customer Service Representatives are needed to answer inbound calls, take orders, screen calls and provide event registration ...

LAST 30 PRESS RELEASES:

Cercus electric stimulation enables cockroach with trajectory control and spatial cognition training

Day-long conference addresses difficult to diagnose lung disease

First-ever cardiogenic shock academy features simulation lab

Thirty-year mystery of dissonance in the “ringing” of black holes explained

Less intensive works best for agricultural soil

Arctic rivers project receives “national champion” designation from frontiers foundation

Computational biology paves the way for new ALS tests

Study offers new hope for babies born with opioid withdrawal syndrome

UT, Volkswagen Group of America celebrate research partnership

New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll

Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes

University of Cincinnati Cancer Center presents research at AACR 2025

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025

AACR: Researchers share promising results from MD Anderson clinical trials

New research explains why our waistlines expand in middle age

Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker

Chips off the old block

Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia

Cutting the complexity from digital carpentry

Lung immune cell type “quietly” controls inflammation in COVID-19

Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity

State and sociodemographic trends in US cigarette smoking with future projections

Young adults drive historic decline in smoking

NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

Chimpanzee stem cells offer new insights into early embryonic development

This injected protein-like polymer helps tissues heal after a heart attack

FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology

In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity

Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects

A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions

[Press-News.org] New drug cuts risk of deadly transplant side effect in half
First study in humans shows promise for preventing graft-versus-host disease following bone marrow transplant